Psychoses Clinical Trial
Official title:
Access, Detection and Psychological Treatments
Schizophrenia is one of society's most costly medical conditions and the most severe among psychiatric disorders. One of the most important and exciting new concepts in psychiatry is that detection and intervention very early in the course of schizophrenia offers what may be the field's best practical hope for realizing substantive improvements in the outcome of schizophrenia or schizophrenia spectrum disorders. Thus, we propose a five year program that focuses on three interconnected major research streams: (1) an evaluation of the effectiveness and cost-effectiveness of a model-driven psychological intervention in preventing or delaying the onset of a psychotic illness; (2) a qualitative study of the pathways to mental health at this time of very high risk; and (3) an exploration of the burden to the healthcare and informal caregiver systems associated with this high risk population.
Research Stream 1:
Treatment and Cost Effectiveness The primary aim of Stream 1 is to evaluate the
effectiveness of a model-driven psychological intervention, CBT in preventing or delaying
the onset of a psychotic illness and to evaluate the effectiveness of CBT in reducing
presenting concerns in a sample of help-seeking individuals who have been operationally
defined to be at ultra high risk of developing a psychotic illness. CBT will be compared to
supportive therapy (ST). We will also examine the cost-effectiveness of a preventive
approach. Using a cost-consequence approach, we will examine the cost-effectiveness of CBT
versus supportive therapy in addressing psychosis in the "ultra high risk" phase from the
perspective of the payer (i.e., the Ministry of Health and Long-Term Care). The hypotheses
are:
(i) The time of conversion will be significantly longer for those in the CBT group compared
to those in the ST condition.
(ii) The mean level of attenuated psychotic symptoms (SOPS ratings ) will be significantly
lower in the CBT group compared to the ST group at the completion of the intervention and at
each follow up point.
(iii) Levels of risk factors (measured by CMRS & GHQ2) will be significantly lower in the
CBT group compared to the ST group at the completion of the intervention and at each follow
up point.
(iv) Levels of depression and anxiety (measured by CDSS, BAS, SPAI2) will be significantly
lower in the CBT group compared to the ST group at the completion of the intervention and at
each follow up point.
(v) Level of social functioning (measured by SFS2) will be significantly higher in the CBT
group compared to the ST group at the termination of the trial and at each follow up point.
(vi) CBT will be more cost-effective than ST.
Research Stream 2:
Pathways to Care The aim of stream 2 is to obtain the in-depth stories of the ways in which
those at ultra high risk of developing a psychotic illness come to seek help from mental
health services. By mental health services, we include the formal system (specialty mental
health & general medical care), lay system (friends, family, self-help), folk system
(alternative healers) and human social service system (clergy, teachers, police). These will
be sought from both the perspective of youth and from the perspective of their significant
others. Multiple case studies using qualitative approaches will focus on the following four
elements: 1) social content; 2) social support system, 3) the illness career; and, 4) the
treatment system (See Appendix A for detailed components within these elements of the
model). These case studies will be employed to further empirically develop theory relating
to pathways to mental health care. Theoretical Propositions: The following four theoretical
propositions related to pathways to mental health care were formulated based on the Network
Episode Model described above. The focus of this stream will be upon the evaluation,
refinement and elaboration of these four theoretical propositions. Multiple case study
methodology will be employed to further empirically develop theory relating to pathways to
mental health care. (i) Family content (e.g., beliefs about and experiences with the medical
system), structure (e.g., size, amount of support) and function (e.g., advice, support or
coercion) have a critical influence on the pathways to mental health care for youth at ultra
high risk for psychosis.(ii) The community and school content, structure and function have a
critical influence on the pathways to mental health care for youth at ultra high risk for
psychosis.(iii) Problem recognition and the illness experience as perceived by the
individual and significant others have a critical influence on the pathways to mental health
care for youth at ultra high risk for psychosis.(iv) The content, structure and function
(e.g. organizational constraints) of the treatment system have a critical influence on the
pathways to mental health care for youth at ultra high risk for psychosis.
Research Stream 3:
Costs of Caring in Psychosis The aim of this third research stream is to explore the burden
to the healthcare system and informal caregivers associated with this ultra high risk
population. We seek to address three primary questions:
(i) What are the key components affecting the costs of caring for the ultra high risk
population? These costs will be considered with respect to both the formal and informal care
providers (i.e., service system and family caregivers, respectively).
(ii) What are other psychological costs of caring that informal caregivers face? (i.e.
modification in parental work schedules to accommodate their child's needs, impact on other
siblings) (iii) Over time, how do the costs of caring change in terms of the economic and
psychological costs?
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01196858 -
Duration of Untreated Psychosis (DUP) and Pathways to Care in Nordland
|
N/A | |
Completed |
NCT00070889 -
Brain Cell Injury in Patients With A First Episode of Psychosis
|
N/A | |
Completed |
NCT00159133 -
Prodrome-Based Early Intervention With Antipsychotics vs. Benzodiazepines in First-Episode Schizophrenia
|
Phase 4 | |
Completed |
NCT00159120 -
Maintenance Treatment vs. Stepwise Drug Discontinuation in First-Episode Schizophrenia
|
Phase 4 | |
Completed |
NCT00087542 -
Treatment of Hallucinosis/Psychosis in Parkinson's Disease by an Investigational Drug
|
Phase 2 | |
Completed |
NCT00095810 -
Aripiprazole in Patients With Psychosis Associated With Parkinson's Disease
|
Phase 4 | |
Recruiting |
NCT00752960 -
DNA Diagnostics for Minimizing Metabolic Side-Effects of Antipsychotics
|
N/A | |
Completed |
NCT00469365 -
Pharmacy Interventions to Improve Chronic Disease Medication Refill
|
Phase 3 | |
Completed |
NCT00491569 -
Sarcosine or D-Serine Add-on Treatment for Chronic Schizophrenia
|
Phase 2 | |
Completed |
NCT00204061 -
Early Pharmacological and Psychological Intervention for Late Prodromal States of Psychosis
|
Phase 4 | |
Completed |
NCT00328276 -
Sarcosine (N-Methylglycine) Monotherapy for Schizophrenia
|
Phase 2 | |
Withdrawn |
NCT00276263 -
Sarcosine Preventive Therapy for Individuals At High Risk for Schizophrenia
|
Phase 2 | |
Completed |
NCT00960219 -
D-amino Acid Oxidase Inhibition (DAAOI-1) add-on Treatment for Chronic Schizophrenia
|
Phase 2 | |
Completed |
NCT03609515 -
Patient-controlled Admissions in Inpatient Mental Health Services
|
N/A |